Dual High Throughput Proteomic and Transcriptomic Screen for Predictive Biomarkers of Everolimus Sensitivity in Pancreatic NET

#1557

Introduction: mTOR inhibitor Everolimus is approved for the treatment of well-differentiated PNET. The heterogeneity of the response rate and the potential toxicity warrant predictive biomarkers.

Aim(s): Define through a dual high throughput proteomic and transcriptomic approach predictive biomarkers of Everolimus sensitivity.

Materials and methods: Fifteen well-differentiated PNET tumors were minced in 300uM slices and cultured for 48h with no drug, Everolimus or BEZ235. Caspase 3 levels assessed by immunohistochemistry at 48h were used to define sensitive and resistant tumors. Transcriptomic profiles were determined and key oncogenic proteins were quantified by reverse phase protein array (RPPA).

Conference: 13th Annual ENETSConcerence (2016)

Presenting Author: CROS J

Authors: Bucau M, Cros J, Raffenne J, Rebours V, Palazzo M,

Keywords: PNET, everolimus, predictive biomarkers,